MedPath

Salbutamol

Generic Name
Salbutamol
Brand Names
Airomir, Airsupra, Combivent, Proair, Proventil, Ventolin
Drug Type
Small Molecule
Chemical Formula
C13H21NO3
CAS Number
18559-94-9
Unique Ingredient Identifier
QF8SVZ843E
Background

Salbutamol is a short-acting, selective beta2-adrenergic receptor agonist used in the treatment of asthma and COPD. It is 29 times more selective for beta2 receptors than beta1 receptors giving it higher specificity for pulmonary beta receptors versus beta1-adrenergic receptors located in the heart. Salbutamol is formulated as a racemic mixture of the R- and S-isomers. The R-isomer has 150 times greater affinity for the beta2-receptor than the S-isomer and the S-isomer has been associated with toxicity. This lead to the development of levalbuterol, the single R-isomer of salbutamol. However, the high cost of levalbuterol compared to salbutamol has deterred wide-spread use of this enantiomerically pure version of the drug. Salbutamol is generally used for acute episodes of bronchospasm caused by bronchial asthma, chronic bronchitis and other chronic bronchopulmonary disorders such as chronic obstructive pulmonary disorder (COPD). It is also used prophylactically for exercise-induced asthma.

Indication

Salbutamol is indicated for (i) the symptomatic relief and prevention of bronchospasm due to bronchial asthma, chronic bronchitis, reversible obstructive airway disease, and other chronic bronchopulmonary disorders in which bronchospasm is a complicating factor, and/or (ii) the acute prophylaxis against exercise-induced bronchospasm and other stimuli known to induce bronchospasm.

Associated Conditions
Asthma, Asthmatic Bronchitis, Bronchial Asthma, Bronchoconstriction, Bronchospasm, Chronic Asthma, Chronic Bronchitis, Cough, Emphysema, Exacerbation of asthma, Exercise-Induced Bronchospasm, Hyperkalemia, Wheezing, Excess mucus or phlegm
Associated Therapies
Airway secretion clearance therapy, Bronchodilation

Respiratory Impedance and Obliterative Bronchiolitis

Not Applicable
Completed
Conditions
Hematopoietic Stem Cell Transplantation
Obliterative Bronchiolitis
Interventions
First Posted Date
2010-12-07
Last Posted Date
2013-01-31
Lead Sponsor
IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genoa, Italy
Target Recruit Count
26
Registration Number
NCT01255449
Locations
🇮🇹

U.O. Medicina Preventiva e del Lavoro, Laboratorio di Fisiopatologia Respiratoria, IRCCS Azienda Ospedaliera Universitaria San Martino - IST Istituto Nazionale per la Ricerca sul Cancro, Genova, Italy

Efficacy of Albuterol in the Treatment of Congenital Myasthenic Syndromes

Phase 1
Completed
Conditions
Congenital Myasthenic Syndrome
Interventions
First Posted Date
2010-09-16
Last Posted Date
2016-01-01
Lead Sponsor
Mayo Clinic
Target Recruit Count
21
Registration Number
NCT01203592
Locations
🇺🇸

Mayo Clinic, Rochester, Minnesota, United States

Optimal Albuterol Regimens for Acute Asthma Exacerbations: DBRCT Pilot Study

Not Applicable
Completed
Conditions
Acute Asthma
Interventions
First Posted Date
2010-09-08
Last Posted Date
2017-09-29
Lead Sponsor
Vanderbilt University Medical Center
Target Recruit Count
16
Registration Number
NCT01196377

Effect of Nebulized Bronchodilators on Heart Rate

Phase 4
Completed
Conditions
Sepsis
COPD
Shock
Interventions
First Posted Date
2010-06-28
Last Posted Date
2015-10-23
Lead Sponsor
Fahim Khorfan, MD
Target Recruit Count
89
Registration Number
NCT01151579
Locations
🇺🇸

Genesys Regional Medical Center, Grand Blanc, Michigan, United States

Characterization of Placebo Responses in Stable Asthma

Not Applicable
Completed
Conditions
Asthma Placebo Effects
Interventions
Drug: placebo inhaler
Procedure: placebo acupuncture
Drug: albuterol
First Posted Date
2010-06-14
Last Posted Date
2017-03-30
Lead Sponsor
Brigham and Women's Hospital
Target Recruit Count
39
Registration Number
NCT01143688
Locations
🇺🇸

Brigham & women's Hospital, Boston, Massachusetts, United States

Comparative Study on the Efficacy and Safety of Procaterol Versus Salbutamol Given Via Metered Dose Inhaler With Spacer in the Management of Acute Asthma Attack in the Emergency Room

Phase 4
Completed
Conditions
Asthma
Interventions
First Posted Date
2010-03-24
Last Posted Date
2010-03-24
Lead Sponsor
Otsuka Pharmaceutical, Inc., Philippines
Target Recruit Count
96
Registration Number
NCT01091337
Locations
🇵🇭

Philippine General Hospital, Manila, Philippines

Bronchodilator Responsiveness in Healthy Young Adults Using Forced Oscillations Technique (FOT)

Not Applicable
Completed
Conditions
Bronchodilation
First Posted Date
2010-02-11
Last Posted Date
2011-01-19
Lead Sponsor
University of Patras
Target Recruit Count
100
Registration Number
NCT01067534
Locations
🇬🇷

University Hospital of Patras, Patras, Greece

Dose-response of Albuterol in Asthmatics

Phase 4
Completed
Conditions
Asthma
First Posted Date
2009-07-17
Last Posted Date
2015-05-05
Lead Sponsor
Nemours Children's Clinic
Target Recruit Count
81
Registration Number
NCT00940927
Locations
🇺🇸

Nemours Children's Clinic, Jacksonville, Florida, United States

Study to Assess the Effect of Salbutamol and Ipratropium Bromide in Chronic Obstructive Pulmonary Disease (COPD) Patients

Phase 4
Completed
Conditions
COPD
Interventions
First Posted Date
2009-06-02
Last Posted Date
2009-06-02
Lead Sponsor
University Hospital, Antwerp
Target Recruit Count
6
Registration Number
NCT00911651
Locations
🇧🇪

Antwerp University Hospital, Antwerp, Belgium

© Copyright 2025. All Rights Reserved by MedPath